Skip to content

Study · Not a test of the peptide alone · 2017

8 results

Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.

Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW

Diabetes, obesity & metabolism31 May 2017Cited by 53 (Europe PMC)

PMID28345814 (opens in a new tab)PMCIDPMC5575470 (opens in a new tab)DOI10.1111/dom.12954 (opens in a new tab)PepBankPUB-28345814
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome

    In obese adults, dapagliflozin plus exenatide caused more nausea than placebo, which diminished over time.

    In plain wordsIn obese adults, nausea was more frequent with dapagliflozin plus exenatide than placebo and diminished over time.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseNausea
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Nausea and injection-site reactions were more frequent with dapagliflozin + exenatide than with placebo and diminished over time.
    1 context sentence
    Summary · context
    They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome

    In obese adults, injection-site reactions were more frequent with dapagliflozin plus exenatide than placebo and diminished over time.

    In plain wordsIn obese adults, injection-site reactions were more frequent with dapagliflozin plus exenatide than placebo and diminished over time.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInjection-site reactions
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    Nausea and injection-site reactions were more frequent with dapagliflozin + exenatide than with placebo and diminished over time.
    1 context sentence
    Summary · context
    They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 03HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In obese adults without diabetes, dapagliflozin plus exenatide sustained weight reductions at 52 weeks.

    In plain wordsIn obese adults without diabetes, dapagliflozin plus exenatide sustained weight reductions.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −4.5 kg
    24 weeks
    Weight change
    −5.7 kg
    52 weeks

    Source sentences

    Summary
    Reductions with dapagliflozin + exenatide at 24 weeks were sustained at 52 weeks, respectively, for body weight (-4.5 and -5.7 kg), total adipose tissue volume (-3.8 and -5.3 L), proportion with prediabetes (34.8% and 35.3%), and SBP (-9.8 and -12.0 mm Hg).
    1 context sentence
    Summary · context
    They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 04HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In obese adults without diabetes, dapagliflozin plus exenatide sustained adipose tissue volume reductions.

    In plain wordsIn obese adults without diabetes, dapagliflozin plus exenatide sustained fat volume reductions.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTotal adipose tissue volume
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight

    Measurements

    Total adipose tissue volume change
    −3.8 L
    24 weeks
    Total adipose tissue volume change
    −5.3 L
    52 weeks

    Source sentences

    Summary
    Reductions with dapagliflozin + exenatide at 24 weeks were sustained at 52 weeks, respectively, for body weight (-4.5 and -5.7 kg), total adipose tissue volume (-3.8 and -5.3 L), proportion with prediabetes (34.8% and 35.3%), and SBP (-9.8 and -12.0 mm Hg).
    1 context sentence
    Summary · context
    They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 05HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In obese adults without diabetes, dapagliflozin plus exenatide sustained reductions in prediabetes prevalence.

    In plain wordsIn obese adults without diabetes, fewer participants had prediabetes during dapagliflozin plus exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePrediabetes prevalence
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Proportion with prediabetes
    34.8%
    24 weeks
    Proportion with prediabetes
    35.3%
    52 weeks

    Source sentences

    Summary
    Reductions with dapagliflozin + exenatide at 24 weeks were sustained at 52 weeks, respectively, for body weight (-4.5 and -5.7 kg), total adipose tissue volume (-3.8 and -5.3 L), proportion with prediabetes (34.8% and 35.3%), and SBP (-9.8 and -12.0 mm Hg).
    1 context sentence
    Summary · context
    They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  6. 06HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In obese adults without diabetes, dapagliflozin plus exenatide sustained systolic blood pressure reductions.

    In plain wordsIn obese adults without diabetes, dapagliflozin plus exenatide sustained blood pressure reductions.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Systolic blood pressure change
    −9.8 mm Hg
    24 weeks
    Systolic blood pressure change
    −12 mm Hg
    52 weeks

    Source sentences

    Summary
    Reductions with dapagliflozin + exenatide at 24 weeks were sustained at 52 weeks, respectively, for body weight (-4.5 and -5.7 kg), total adipose tissue volume (-3.8 and -5.3 L), proportion with prediabetes (34.8% and 35.3%), and SBP (-9.8 and -12.0 mm Hg).
    1 context sentence
    Summary · context
    They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  7. 07HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In obese adults, weight, blood pressure and glycaemia effects were similar after switching to or continuing dapagliflozin plus exenatide.

    In plain wordsIn obese adults, outcomes were similar after switching to or continuing dapagliflozin plus exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeExtension outcomes by initial assignment
    Study

    n: not reported in source

    Comparator
    Switch from placebo to dapagliflozin plus exenatide versus continued dapagliflozin plus exenatide
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight

    Source sentences

    Summary
    Effects on body weight, SBP and glycaemia at 52 weeks with placebo → dapagliflozin + exenatide were similar to those observed with continuation of dapagliflozin + exenatide.
    1 context sentence
    Summary · context
    They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  8. 08HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialSafety outcome

    In obese adults, adverse event-related withdrawals showed no clear difference between placebo and dapagliflozin plus exenatide periods.

    In plain wordsIn obese adults, withdrawals due to adverse events showed no clear difference between placebo and dapagliflozin plus exenatide periods.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAdverse event-related withdrawal
    Study

    n: not reported in source

    Comparator
    Placebo periods
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No clear difference in adverse event-related withdrawals between placebo and active treatment periods was observed.
    1 context sentence
    Summary · context
    They entered an open-label extension from 24 to 52 weeks during which all participants received active treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03361098

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

Amsterdam UMC, location VUmcn = 6518 Sept 2017 to 25 Mar 2020

Type 2 Diabetes Mellitus · Obesity

Trial pageClinicalTrials.govUpdated 11 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.